About Endo International
Endo International is a publicly listed company based in Malvern (United States) founded in 1997. Global pharmaceutical company manufacturing branded, generic formulations, and OTC medicines. The company has 1,431 employees. Endo International has completed 14 acquisitions, including American Medical Systems, Auxilium Pharmaceuticals and BML Pharma. Its website endo.com draws about 10 thousand monthly visits. Its Indian entity Par Formulations Private Limited reported revenue of ₹1,462 Cr. Endo International offers products and services including Sterile Injectables and Generics. Its focus areas include Diversified Pharmaceuticals and Drugs. Its competitors include Roivant Sciences, Gilead and Lilly; 1 of its 3 listed competitors has raised funding.
Company details
Endo International, backed by 171246909.0 from HHS, Kelso Company, focuses on providing healthcare solutions, diversified pharmaceuticals, and drugs. Global pharmaceutical company manufacturing branded, generic formulations, and OTC medicines. Driving innovation, growth, and excellence in its industry sectors. It continues to evolve, meeting industry challenges with strategic approaches.
- Headquarters Malvern, United States
- Employees 1,431
- Stage Public
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Website endo.com
- Social LinkedIn X
- Legal Name Endo, Inc.
- Date of Incorporation 22 Sep, 1982
- Indian entity revenue₹1,462 Cr
FY 2025 · +5% YoY
- Indian entity net profit₹28.41 Cr
FY 2025 · 2% margin
- Indian entity EBITDA₹253 Cr
FY 2025 · 17% margin
- Latest Funding Round$170.57M (USD), Post-IPO
Mar 2024
- InvestorsHHS
& 1 more
- Employee Count1,431
- Investments & AcquisitionsAmerican Medical Systems
& 13 more
Associated legal entities of Endo International
Endo International operates through Par Formulations Private Limited (active). Its filings, financials, charges and directors are on the company page.
| Legal entity | Status | Incorporated | Registered in | Revenue (FY 2025) | Employees | Directors | Company page |
|---|---|---|---|---|---|---|---|
| Par Formulations Private Limited CIN U33111TN1982PTC009602 | Active | 22 Sep 1982 | Chennai, Tamil Nadu | ₹1,462 Cr | 1,304 | 3 | View details |
Products & Services of Endo International
Endo International offers a comprehensive portfolio of products and services, including Sterile Injectables and Generics.
Products for hospital use in reducing complexity and enhancing patient care
High-quality generic medicines for retail and pharmacy distribution
Funding Insights of Endo International
- Total Rounds 3
- Last Round Post-IPO — $170.57M
- Investors Count 2
All 3 funding rounds of Endo International with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Mar 2024 | $170.57M | Post-IPO | – | – | – |
| Feb 2011 | $672,685 | Grant | – | – | |
| Jun 1997 | Unspecified | – | – |
2 investors in total: 2 institutional.
Investors in Endo International
Endo International has secured backing from 2 investors, including institutional and venture fund investors. Prominent investors backing the company include HHS and Kelso & Company.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Private equity investments are directed toward multiple sectors. | kelso.com | New York, United States | ||
Public health and human services are overseen by HHS. | 1953 | hhs.gov |
Investor details for Endo International
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Board of directors of Par Formulations Private Limited (Endo International)
Par Formulations Private Limited is the primary company behind Endo International. The board of Par Formulations Private Limited currently have 2 directors; the longest-serving is Chitti Babu Sampath Kumar, appointed in 2017. 27 earlier directors have ceased.
| Director | Designation | Appointed | Tenure | Entity |
|---|---|---|---|---|
| Chitti Babu Sampath Kumar DIN 07853043 | Whole-time director | 28 Jun 2017 | 9 yrs 4 mo | Par Formulations Private Limited |
| Anand Amrit Raj DIN 09622306 | Director | 27 May 2022 | 4 yrs 5 mo | Par Formulations Private Limited |
People of Endo International
182 people are tracked at Endo International (68 in leadership, 7 in board & advisors, 107 in team); the tracked headcount is 1,431.
| Name | Role | Group |
|---|---|---|
Michael Randolph | Global Head, Manufacturing Operations | Leadership |
Blaise Coleman | President & CEO | Leadership |
Joan Ramella | Associate Director Clinical Operations | Leadership |
Mick McGuinness | Global Head, Quality & Compliance | Leadership |
Matthew J. Maletta | EVP & Chief Legal Officer | Leadership |
Tracy Basso | Chief Human Resources Officer | Leadership |
Karen Giandonato | Sr. Director, Corporate HR Operations | Leadership |
James Papp | Head, Endo Ventures Limited & SVP of Global Supply Chain | Leadership |
Cheryl Stouch | SVP, Information Technology & Chief Information Officer | Leadership |
Patrick Barry | EVP & Chief Commercial Officer | Leadership |
Richard Hooper | Director Strategic Sourcing | Leadership |
Heath Weber | Director, Web Center Of Excellence | Leadership |
Melvin Prasad | National Sales Director | Leadership |
Phillip Wydro | Executive Director - IT Enterprise ERP & Finance | Leadership |
Maritza Russo | Associate Director, Talent Acquisition | Leadership |
Tim Garrett | A. Director, Managed Care | Leadership |
Dayna Sracic | Executive Director, Consumer Marketing | Leadership |
David Hughes | Associate Director Global Quality Systems | Leadership |
Susan Williamson | SVP & Chief Compliance Officer | Leadership |
Lou Donato | Executive Director, Corporate Compliance | Leadership |
162 more people are available in the full profile.
Complete people profiles for Endo International
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Financials of Endo International
Figures of Par Formulations Private Limited, the primary company behind Endo International, for FY 2025. Revenue was ₹1,462 Cr (+5% year on year). Net profit was ₹28.41 Cr (2% margin). EBITDA was ₹253 Cr (17% margin). Revenue has grown at a compounded annual rate of +13% over three years and +19% over five years.
- ₹1,462 CrRevenue · FY 2025 · +5% YoY
- ₹28.41 CrNet profit · 2% margin
- ₹253 CrEBITDA · 17% margin
- ₹2.14 CrPaid-up capital
- 1,304Employees (provident fund records)
- +13%Revenue CAGR, 3 years
- +19%Revenue CAGR, 5 years
Balance sheet, profit and loss, cash flow and ratios of Par Formulations Private Limited are on its company page.
Detailed financial statements for Endo International
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Endo International
Endo International has strategically engaged in corporate development activities, having acquired 14 companies. Notable acquisitions include American Medical Systems, Auxilium Pharmaceuticals and BML Pharma.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Injectable collagenase is developed for multiple medical indications. | biospecifics.com | Lynbrook, United States | 1957 | Oct 2020 | •••• | |
Energy and telecommunications cable systems are manufactured and distributed internationally. | somersettherapeutics.com | Somerset, United States | 2015 | Apr 2018 | $32M | |
Pharmaceutical products are developed for endocrinology, orthopedics, and urology. | parpharm.com | Woodcliff Lake, United States | 1978 | May 2015 | $8.05B | |
Developer of therapeutics and drug-device combinations for urology and sexual health | auxilium.com | Philadelphia, United States | 1999 | Oct 2014 | •••• | |
Generic drugs are manufactured and distributed by DAVA Pharmaceuticals. | davapharma.com | Fort Lee, United States | 2004 | Jun 2014 | $600M | |
Innovative pharmaceutical products are acquired and in-licensed by Paladin Labs. | paladin-labs.com | Montreal, Canada | 1983 | Nov 2013 | •••• | |
Pharmaceutical products are manufactured and compounded in the United States. | bocapharmacal.com | Coral Springs, United States | 1998 | Aug 2013 | $225M | |
Comprehensive EMR software for urologists is developed and offered. | intuitivemedical.com | Springfield, United States | 2005 | Jun 2011 | •••• | |
Devices for the treatment of pelvic disorders | americanmedicalsystems.com | Minnetonka, United States | 1972 | Apr 2011 | $2.9B | |
Provider of arbitration, mediation, and legal consulting for international commercial disputes | qualitestrx.com | Huntsville, United States | 1983 | Sep 2010 | $1.2B |
Complete acquisition details for Endo International
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of Endo International
14 dated milestones of Endo International across 27 years, from founding to its latest funding, stage changes and deals.
- Founded Endo International is founded.
- Funding First funding round.
- Acquisition Acquires Qualitest Pharmaceuticals.
- Acquisition Acquires American Medical Systems.
- Acquisition Acquires Intuitive Medical.
- Acquisition Acquires Boca Pharmacal.
- Acquisition Acquires Paladin Labs.
- IPO Lists on the stock exchange (IPO).
- Acquisition Acquires DAVA Pharmaceuticals.
- Acquisition Acquires Auxilium Pharmaceuticals.
- Acquisition Acquires Par Pharmaceutical Companies.
- Acquisition Acquires Somerset Therapeutics.
- Acquisition Acquires BioSpecifics Technologies.
- Funding Latest funding round, Post-IPO, of $170.6M.
Competitors of Endo International
Endo International has 3 listed competitors in our database, 1 of them funded. They include Roivant Sciences, Gilead and Lilly.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| roivant.com | 2014 | New York, United States | $1.3B | 662 | Therapeutics for neurology, oncology, rare, and endocrinology diseases are developed. | |
| gilead.com | 1987 | Foster, United States | 4,267 | Developer of medicines to treat HIV/AIDS, liver diseases, cancer & others | ||
| lilly.com | 1876 | United States | 39,000 | Traditional pharmaceutical medicines are developed for multiple health fields. |
Detailed competitors of Endo International
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Endo International
The website of Endo International (endo.com) receives about 10K visits a month and ranks #2,323,439 among all websites worldwide, #3,177 in Biotechnology and Pharmaceuticals.
- Monthly visits10K
▼ 1.9% vs previous month
- Unique visitors5K
per month
- Global rank#2,323,439
among all websites
- Category rank#3,177
Health · Biotechnology and Pharmaceuticals
- Bounce rate49%
- Pages per visit1.5
- Average visit15 sec
- DevicesDesktop 31% · Mobile 69%
Websites whose visitors overlap most with Endo International. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| paladin-labs.com | 100% | View details | |||
| pfizer.com | 94% | 1.9M | #24,984 | View details | |
| merck.com | 91% | 656.8K | #78,842 | View details | |
| jazzpharma.com | 83% | 86.1K | #530,349 | View details | |
| elan.com | 83% | View details | |||
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 36 similar websites and full traffic analytics for Endo International
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 36 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in Pharmaceuticals & Distribution
3 companies that operate in the same segment as Endo International (Pharmaceuticals & Distribution) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Therapeutics for neurology, oncology, rare, and endocrinology diseases are developed. | 2014 | New York, New York, United States | USD 1.3 B | USD 8.26 M | 750 | |
Developer of pharmaceutical products for treating multiple diseases | 1980 | Thousand Oaks, California, United States | USD 33.23 B | 28,000 | ||
Biopharmaceutical research and drug development are conducted globally by AbbVie. | 2012 | Chicago, Illinois, United States | USD 5.33 B | 55,000 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Endo International
Complete news archive for Endo International
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Endo International
Endo International was founded in 1997.
Endo International is headquartered in Malvern, United States. It is registered at Malvern, Pennsylvania, United States.
Endo International has 1,431 employees.
The primary company behind Endo International, Par Formulations Private Limited, reported revenue of ₹1,462 Cr for FY 2025, up 5% year on year.
Endo International, backed by 171246909.0 from HHS, Kelso Company, focuses on providing healthcare solutions, diversified pharmaceuticals, and drugs. Global pharmaceutical company manufacturing branded, generic formulations, and OTC medicines. Driving innovation, growth, and excellence in its industry sectors. It continues to evolve, meeting industry challenges with strategic approaches.
Endo International's top competitors include Roivant Sciences, Lilly and Gilead.
Endo International offers Sterile Injectables and Generics.
Endo International has made 14 acquisitions, including American Medical Systems, Auxilium Pharmaceuticals, and BML Pharma.
Endo International has 2 investors. Key investors include HHS, and Kelso & Company.
Endo International operates through Par Formulations Private Limited.
The legal entities of Endo International currently have 3 directors, including Chitti Babu Sampath Kumar, Anand Amrit Raj, Nazneen Nasir Khan.